March 18, 2022

Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene

Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene

Hear how Jay Mai, MD, PhD, went from his benchtop years at the NIH to a blockbuster launch at Celgene (think, Revlimid, after stints at Novartis and J&J along the way) – to spearhead the multi-asset juggernaut that is the oncology company, Antengene. From it’s “license and build” beginnings, to the advent of in-house programs (15 assets in all) Antengene is poised to hit multiple oncology targets, from a small molecule ERK 1/2 inhibitor, to a bispecific for PD-L1/ 4-1BB. And did I mention they have a global license, and are expanding indications for XPOVIO? Give a listen…